Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.
Hepatocellular Carcinoma
PROCEDURE: Transcatheter arterial chemoembolization (TACE)|DRUG: Telbivudine
Number of Participants with Adverse Events as a Measure of Safety and Tolerability, 6 months
Overall survival, 2 years
The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.